

Title: Association of upper respiratory *Streptococcus pneumoniae* colonization with SARS-CoV-2 infection among adults

Authors: Anna M. Parker¹, Nicole Jackson¹, Shevya Awasthi¹, Hanna Kim¹, Tess Alwan¹, Anne L. Wyllie², Alisha B. Baldwin³, Nicole B. Brennick³, Erica A. Moehle³, Petros Giannikopoulos³, Katherine Kogut⁴, Nina Holland⁴, Ana Mora-Wyrobek⁴, Brenda Eskenazi⁴, Lee W. Riley¹, Joseph A. Lewnard^{1,5,6,*}

Affiliations:

1. Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
2. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut 06510, United States
3. Innovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States
4. Center for Environmental Research & Community Health, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
5. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
6. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States

* Address for correspondence:

Joseph Lewnard
2121 Berkeley Way
Berkeley, California 94720
United States
jLewnard@berkeley.edu
(847) 507-6115

Running head: Pneumococcal/SARS-CoV-2 interactions

Key points:

- In an adult ambulatory and community sample, SARS-CoV-2 infection was more prevalent among pneumococcal carriers than non-carriers.
- Associations between pneumococcal carriage and SARS-CoV-2 infection were strongest among adults reporting acute symptoms and receiving SARS-CoV-2 testing in a clinical setting.

Word count

Key points: 39

Abstract: 250

Main text: 2,993

ABSTRACT

Background: *Streptococcus pneumoniae* interacts with numerous viral respiratory pathogens in the upper airway. It is unclear whether similar interactions occur with SARS-CoV-2.

Methods: We collected saliva specimens from working-age adults receiving SARS-CoV-2 molecular testing at outpatient clinics and via mobile community-outreach testing between July and November 2020 in Monterey County, California. Following bacterial culture enrichment, we tested for pneumococci by quantitative polymerase chain reaction (qPCR) targeting the *lytA* and *piaB* genes, and measured associations with SARS-CoV-2 infection via conditional logistic regression.

Results: Analyses included 1,278 participants, with 564 enrolled in clinics and 714 enrolled through outreach-based testing. Prevalence of pneumococcal carriage was 9.2% (117/1,278) among all participants (11.2% [63/564] clinic-based testing; 7.6% [54/714] outreach testing). Prevalence of SARS-CoV-2 infection was 27.4% (32/117) among pneumococcal carriers and 9.6% (112/1,161) among non-carriers (adjusted odds ratio [aOR]: 2.73; 95% confidence interval: 1.58-4.69). Associations between SARS-CoV-2 infection and pneumococcal carriage were enhanced in the clinic-based sample (aOR=4.01 [2.08-7.75]) and among symptomatic participants (aOR=3.38 [1.35-8.40]), when compared to findings within the outreach-based sample and among asymptomatic participants. Adjusted odds of SARS-CoV-2 co-infection increased 1.24 (1.00-1.55)-fold for each 1-unit decrease in *piaB* qPCR C_T value among pneumococcal carriers. Last, pneumococcal carriage modified the association of SARS-CoV-2 infection with recent exposure to a suspected COVID-19 case (aOR=7.64 [1.91-30.7] and 3.29 [1.94-5.59]) among pneumococcal carriers and non-carriers, respectively).

Conclusions: Associations of pneumococcal carriage detection and density with SARS-CoV-2 suggest a synergistic relationship in the upper airway. Longitudinal studies are needed to determine interaction mechanisms between pneumococci and SARS-CoV-2.

Key words: Pneumococcus; SARS-CoV-2; viral-bacterial interaction; carriage

INTRODUCTION

Interactions involving *Streptococcus pneumoniae* and respiratory viruses feature in the natural history of multiple clinical conditions. Pneumococcal pneumonia and invasive pneumococcal disease (IPD) incidence rates align with seasonal influenza and respiratory syncytial virus (RSV) transmission,^{1,2} and severe pneumococcal infections are prominent sequelae of viral respiratory disease.³ Interactions also arise earlier in the clinical course, including when symptoms are absent. Epidemiologic studies of influenza virus, RSV, human rhinoviruses, and endemic human coronaviruses have revealed frequent co-detection of pneumococci in the upper airway, often in association with increased density of bacterial shedding.⁴⁻¹¹ Likewise, experimental challenge models in animals¹² and humans^{13,14} have revealed effects of pneumococcal carriage on influenza virus acquisition and immune response, while epidemiologic studies have identified increased risk of viral acquisition and acute respiratory infection associated with the presence and density of pneumococcal carriage.¹⁵

It is unclear whether similar interactions occur between pneumococci and SARS-CoV-2. Contrary to experience with influenza, early investigations identified low risk of severe secondary pneumococcal infections among COVID-19 patients,¹⁶ although such studies may have been limited by choice of pneumococcal detection methods and prevalent antibiotic prescribing for COVID-19 patients during the early pandemic.^{17,18} Among healthcare workers in the United Kingdom, SARS-CoV-2 infection was associated with three-fold higher likelihood of molecular detection of pneumococcal carriage in saliva; moreover, pneumococcal carriers experienced diminished IgA and CD4⁺ T-cell responses to SARS-CoV-2 after recovery.¹⁹ SARS-CoV-2 acquisition concurrent with or shortly following IPD was associated with enhanced mortality in a UK surveillance study.²⁰ Last, among adults aged ≥65 years in the United States, receipt of 13-valent pneumococcal conjugate vaccine (PCV13) was associated with reduced risk of COVID-19 diagnosis, hospital admission, and mortality.²¹ These findings reflect moderate PCV effectiveness against virus-associated lower respiratory tract infection (LRTI) and pneumonia among children and adults in prior studies.²²⁻²⁵

To understand potential interactions between pneumococci and SARS-CoV-2, we evaluated pneumococcal carriage within a study of SARS-CoV-2 infection among adult farmworkers in Monterey County, California undertaken between July and November, 2020.²⁶ We aimed to assess whether pneumococcal carriage was associated with SARS-CoV-2 infection, and to evaluate how this association varied according to pneumococcal carriage density and clinical symptoms.

METHODS

Study setting and recruitment

Primary study methods and findings have been reported previously.²⁶⁻²⁸ Briefly, we enrolled adults currently or previously employed in agricultural work through no-cost, point-of-care molecular SARS-CoV-2 testing at ambulatory outpatient clinics and mobile community outreach venues operated by Clínica de Salud del Valle de Salinas (CSVS) throughout Monterey County, California, from 16 July to 30 November, 2020. CSVS is a Federally-Qualified Health Center serving >50,000 patients, primarily focused on healthcare for local agricultural workers and their families. Most farmworkers in the region are Latino and live below the federal poverty line.²⁹ SARS-CoV-2 test positivity among these farmworkers was higher than among other adults in Monterey County throughout the study period.²⁶

Healthcare providers at CSVS recommended SARS-CoV-2 testing for all patients, regardless of symptoms, during the study period. Outreach testing was also conducted at community sites throughout the Salinas Valley, including low-income and agricultural employer-provided housing facilities, agricultural fields, and health fairs. Individuals eligible for the primary study were nonpregnant adult farmworkers aged ≥ 18 years who received SARS-CoV-2 testing at CSVS, who had not previously participated in the study, and who spoke sufficient Spanish or English to provide consent and complete study procedures. For this ancillary study of pneumococcal carriage, we expanded recruitment to include any other adults (not exclusively farmworkers) who received SARS-CoV-2 testing at CSVS, who spoke Spanish or English and agreed to provide a saliva sample.

Participants provided ≥ 3 mL of saliva passively pooling in the front of the mouth into ≥ 20 mL screw-top collection tubes. Participants responded to a standardized survey covering demographics, clinical symptoms, and recent exposures by telephone interview within 48 hours of their testing appointment, before SARS-CoV-2 testing results were notified. Participants who were not farmworkers and enrolled in the pneumococcal sub-study only answered a shortened survey.

Outcome definitions

We determined pneumococcal carriage via quantitative polymerase chain reaction (qPCR) assays targeting the *lytA* and *piaB* genes, using bacterial DNA extracted after a culture-enrichment step according to previously-validated protocols³⁰ (**Text S1**). Samples with *lytA* cycle threshold (C_T) values < 40 were tested for the *piaB* gene and were considered to contain pneumococci if both *lytA* and *piaB* C_T values were < 40 (**Table S1**). We additionally report results applying a more stringent threshold of *lytA* and *piaB* C_T values < 35 . Clinical testing for SARS-CoV-2 from oropharyngeal specimens was conducted via the qualitative Aptima SARS-CoV-2 (Hologic; Marlborough, Massachusetts, US) transcription-mediated amplification (TMA) assay. We considered individuals with positive results for SARS-CoV-2 by this clinical test to be infected. For secondary analyses addressing SARS-CoV-2 viral abundance, we also used C_T values from qPCR-based detection of the SARS-CoV-2 nucleocapsid (N) and structural envelope protein (E) genes in saliva specimens (**Text S1**).

Statistical analysis

We first compared prevalence of SARS-CoV-2 infection among pneumococcal carriers and non-carriers. We fit conditional logistic regression models defining SARS-CoV-2 infection as the outcome and pneumococcal carriage as the primary exposure of interest, with strata for participants' recruitment setting (clinic-based testing or mobile outreach testing) to address differences in the populations reached. We computed adjusted odds ratios (aORs) adjusting for risk factors including participants' age, sex, body mass index (BMI), community of residence, current or former smoking, residence type, educational background, household annual income,

language spoken, exposure to children aged <5 years, and potential COVID-19 related exposures and risk behaviors in the prior two weeks. These included contact with a confirmed or suspected COVID-19 case, mask-wearing in indoor public settings, attendance at indoor gatherings with individuals from outside participants' households, and regular handwashing. We repeated analyses within two sets of subgroups: participants recruited in clinic-based or mobile outreach testing venues, and participants who reported experiencing or not experiencing clinical symptoms within 2 weeks before testing. As secondary analyses, we also fit models defining pneumococcal carriage as *lytA* and *piaB* $C_T < 35$.

To determine if associations varied according to pneumococcal density, we fit conditional logistic regression models partitioning pneumococcal carriage according to *lytA* and *piaB* C_T in the ranges of 35-39.9, 30-34.9, and <30. We also fit models subset to participants carried pneumococci, within which we defined *lytA* and *piaB* C_T as continuous quantitative covariates. To determine if SARS-CoV-2 abundance was associated with pneumococcal detection or density, we also fit regression models relating C_T values (as continuous outcomes) for the SARS-CoV-2 N and E genes in saliva to pneumococcal detection. Each of these analyses adjusted for the covariates included in primary analyses.

Last, we sought to determine whether the association between recent SARS-CoV-2 exposure and risk of infection differed in association with pneumococcal carriage detection. We conducted analyses considering two distinct SARS-CoV-2 exposure definitions: self-reported contact with any individual experiencing acute upper respiratory symptoms ("suspected" exposure; expected to provide a sensitive albeit non-specific indicator), and notification of exposure to a confirmed SARS-CoV-2 case ("confirmed" exposure; expected to provide a specific indicator, although with low sensitivity since few exposures are notified). Conditional logistic regression models again defined strata by clinic-based or outreach test setting and controlled for all covariates included in primary analyses.

Multivariate-adjusted analyses were subset to individuals who participated in the primary study and thus completed the full telephone-based survey. Expanded data (including pneumococcal sub-study participants) are presented separately, where applicable, for analyses of pneumococcal and SARS-CoV-2 co-detection

without covariate adjustment. Missing covariate data where participants in the primary study responded to questions with “Don’t know” or “Refuse” were populated by multiple imputation with five pseudo-datasets. We conducted analyses in R version 4.1.3.

RESULTS

We enrolled 1,309 participants, including 1,115 in the primary study among farmworkers and 194 in the pneumococcal sub-study only. Saliva specimens were obtained from 1,306 individuals. We excluded 8 samples from individuals who participated in the primary study but did not meet eligibility criteria, and 15 samples due to quality concerns (insufficient volume, label mismatch, or contamination). Additionally, SARS-CoV-2 testing results were inconclusive or unavailable for 5 participants. Final analyses included 1,278 participants (1,095 in the primary study and 183 in the expanded sub-study). Of this sample, 564 and 714 participants were enrolled in clinic-based and mobile outreach testing venues, respectively, among whom 35.7% (199/558, excluding participants missing responses) and 25.4% (181/714), respectively, reported experiencing any solicited clinical symptoms within two weeks before testing (**Table S2**; **Table S3**).

Pneumococcal carriage prevalence was 9.2% (117/1,278) overall (11.2% [63/564] and 7.6% [54/714] in clinic-based and outreach testing, respectively; **Table 1**; **Table S4**). Within the clinic-based sample, prevalence of SARS-CoV-2 infection was 41.3% (26/63) among pneumococcal carriers and 13.8% (69/501) among non-carriers. Within the outreach sample, prevalence of SARS-CoV-2 infection was 11.1% (6/54) among pneumococcal carriers and 6.5% (43/660) among non-carriers. Similar patterns held in analyses defining pneumococcal carriage according to a *lytA* and *piaB* $C_T < 35$ criterion, with SARS-CoV-2 detected among 34.0% (16/47) of pneumococcal carriers and 10.8% (113/1,048) of non-carriers. Higher point estimates of SARS-CoV-2 infection prevalence among pneumococcal carriers held within strata defined by age, sex, language, country of birth, community of residence, exposure to household crowding, income, education level, occupation, housing type, BMI, cigarette smoking, COVID-19 risk behaviors, and presence or absence of symptoms (**Table 2**).

Adjusted odds of SARS-CoV-2 infection were 2.73 (1.58-4.69) fold higher among pneumococcal carriers than non-carriers (**Table 3**). Corresponding aOR estimates among participants enrolled in clinic-based and outreach testing were 4.01 (2.08-7.75) and 0.95 (0.20-4.44), respectively. In expanded analyses including participants recruited into the pneumococcal sub-study, the unadjusted OR of SARS-CoV-2 infection associated with pneumococcal carriage in outreach-based test settings was 1.80 (0.73-4.45; **Table S5**), whereas associations within other strata more closely resembled those estimated within the primary study population.

Among participants within the primary study reporting any solicited symptoms, pneumococcal carriage was associated with 3.38 (1.35-8.40) fold higher adjusted odds of SARS-CoV-2 infection, while among participants reporting no symptoms, pneumococcal carriage was associated with 2.79 (1.26-6.24) fold higher adjusted odds of SARS-CoV-2 infection (**Table 3**). The strongest association between pneumococcal carriage and SARS-CoV-2 infection was apparent among symptomatic individuals enrolled in clinic-based testing (aOR=6.12 [1.87-20.5]). However, our analyses did not identify specific clinical symptoms associated with pneumococcal carriage or co-detection with SARS-CoV-2 (**Table S6**; **Table S7**).

Among pneumococcal carriers within the primary study with *piaB* C_T values of 35-39.9, 30-34.9, and <30, prevalence of SARS-CoV-2 infection was 21.2% (11/52), 26.7% (8/30), and 38.1% (8/21; **Table 4**). Relative to participants who did not carry pneumococcus, adjusted odds of SARS-CoV-2 infection were 1.73 (0.80-3.74), 3.38 (1.35-8.40), and 5.77 (2.06-16.4) fold higher among those who carried pneumococci with *piaB* C_T values of 35-39.9, 30-34.9, and <30, respectively. Defining *piaB* C_T values as a continuous exposure, adjusted odds of SARS-CoV-2 infection increased 1.24 (1.00-1.55) fold for each 1- C_T decrease among participants carrying pneumococci. In agreement with this pattern, the association of SARS-CoV-2 infection with pneumococcal carriage was strengthened when applying a more stringent definition of pneumococcal carriage as *lytA* and *piaB* C_T <35 (aOR=4.53 [2.20-9.41] vs. 2.73 [1.58-4.69] for *lytA* and *piaB* C_T <40; **Table S8**). Although C_T values were positively correlated for *lytA* and *piaB*, we did not identify consistent associations of SARS-CoV-2 infection with *lytA* C_T values among pneumococcal carriers (**Table 4**; **Figure S1**). Likewise, C_T values for the SARS-CoV-2 N and E genes in saliva specimens were not associated with pneumococcal detection or with *lytA* and *piaB* C_T values (**Table S9**; **Figure S2**).

Among participants in the primary study who reported no suspected or notified SARS-CoV-2 exposure within 2 weeks before testing, prevalence of SARS-CoV-2 infection was 19.2% (15/78) among pneumococcal carriers and 7.9% (61/769) among non-carriers (**Table 5**). In contrast, 69.2% (9/13) of pneumococcal carriers and 26.1% (30/115) of non-carriers who reported suspected exposure tested positive for SARS-CoV-2 infection. The aOR of SARS-CoV-2 infection associated with suspected exposure were 7.64 (1.91-30.7) among pneumococcal carriers and 3.29 (1.94-5.59) among non-carriers. These differences in aOR point estimates held within analyses restricted to participants reporting such exposures in the home (aOR=6.66 [1.32-33.0] for carriers and 3.99 [2.06-7.67] for non-carriers) and workplace (aOR=6.25 [1.00-38.0] for carriers and 2.26 [1.17-4.38] for non-carriers). A similar pattern was apparent for participants who reported that they were notified of exposure to a confirmed COVID-19 case, although such analyses were underpowered due to the low frequency of notified exposures. The aOR of SARS-CoV-2 infection associated with notified exposure was 2.14 (0.28-16.0) among pneumococcal carriers and 0.83 (0.37-1.85) among non-carriers.

DISCUSSION

We identify a synergistic association between pneumococcal carriage and SARS-CoV-2 infection among adults tested in ambulatory clinics and community settings. This association was strongest among participants recruited through clinical SARS-CoV-2 testing and those experiencing acute COVID-19 symptoms. Among pneumococcal carriers, adjusted odds of concurrent SARS-CoV-2 infection increased 24% for each 1-unit decrease in *piaB* C_T , indicating a density-dependent relationship. Last, the increase in odds of SARS-CoV-2 infection associated with recent exposure to a symptomatic individual was roughly two-fold higher among pneumococcal carriers as compared to non-carriers. Collectively, our findings are consistent with the hypothesis of interactions between pneumococci and SARS-CoV-2 in the upper respiratory tract.

In agreement with our findings, a prior study reported that pneumococcal carriage was detected more often among adults with asymptomatic or mild SARS-CoV-2 infection than among uninfected adults, and was

associated with reduced cellular and mucosal immune responses to SARS-CoV-2.¹⁹ Similar interactions have been reported in studies involving other respiratory viruses,⁴⁻¹¹ which have further documented increased pneumococcal density in the upper airway during viral infection.^{5,7-9} While cross-sectional epidemiologic studies cannot distinguish interaction mechanisms underlying these findings—such as pneumococcal outgrowth during viral infection, or facilitation of viral infection during pneumococcal carriage—several studies in mouse models have suggested facilitative interactions may be bidirectional. Challenge with wild-type influenza A virus or live attenuated influenza vaccine extended the duration of pneumococcal carriage in mice, regardless of whether exposure to pneumococci preceded or followed exposure to influenza.¹² Additionally, pneumococcal/SARS-CoV-2 coinfection was associated with enhanced mortality in mice, regardless of the order of challenge with SARS-CoV-2 and pneumococci.³¹ Last, in humans, experimentally-induced pneumococcal colonization dampened mucosal responses to subsequent challenge with live attenuated influenza vaccine.¹³

In contrast to the observed associations of pneumococcal density with SARS-CoV-2 presence or absence, SARS-CoV-2 C_T values were not associated with pneumococcal carriage or density in our study. This circumstance may owe to pronounced temporal variability in SARS-CoV-2 viral load over the course of infection.³² Importantly, our study could not account for time since SARS-CoV-2 acquisition, which is a primary determinant of viral load and may have influenced the findings.

Associations of recent suspected or notified SARS-CoV-2 exposure with risk of infection were stronger among pneumococcal carriers than non-carriers in our study. As typical durations of pneumococcal carriage among adults exceed the 2-week recall period of this exposure,³³ pneumococcal colonization likely preceded SARS-CoV-2 exposure for most study participants with both pathogens detected. At least two interpretations of this finding are possible. First, our finding may signify heightened risk of SARS-CoV-2 infection, given exposure, in the context of nasopharyngeal inflammation induced by pneumococcal colonization. In support of this hypothesis, pre-existing pneumococcal carriage has been found to predict increased risk of new-onset of virus-associated acute respiratory infections among children.¹⁵ In another study among children, pneumococcal carriage density was found to increase markedly with acquisition of RSV or rhinoviruses,³⁴ although such increases could also be driven by a loss of control of existing pneumococcal colonization following viral

acquisition.³⁵ An alternative interpretation may thus view our finding as an artifact of enhanced pneumococcal outgrowth associated with recent SARS-CoV-2 exposure and acquisition. If such outgrowth is transient in nature, higher pneumococcal density (and thus pneumococcal carriage detection) could be associated with more recent SARS-CoV-2 acquisition, thereby accounting for stronger associations between SARS-CoV-2 infection and exposure in the prior 2 weeks among individuals found to carry pneumococci. As our cross-sectional study design cannot distinguish between these hypotheses, longitudinal studies relating baseline pneumococcal carriage status to risk of subsequent viral acquisition are needed.

Our study has several limitations. Recruitment of farmworkers in low-income communities indicates that absolute estimates of prevalence of pneumococcal carriage and SARS-CoV-2 infection are not externally generalizable. Our data do not encompass potential social linkages among participants, who in some instances may have lived or worked together. As recruitment for this study occurred in summer and fall of 2020, cases in our study were not infected with recent SARS-CoV-2 variants of concern. While our analysis demonstrated density-dependent relationships between pneumococcal carriage and SARS-CoV-2 infection based on *piaB* C_T values, these readings were taken following a culture enrichment step. Measures of bacterial abundance obtained prior to culture enrichment would be expected to better represent carriage density in the host, although previous studies have demonstrated strong correlations in pneumococcal C_T values before and after culture enrichment.^{36,37} Last, our study population was recruited in ambulatory care settings and outreach testing venues, and does not represent the full spectrum of COVID-19 disease severity including cases requiring hospital or intensive care unit admission. Observed associations should thus be interpreted as markers of pathogen interactions either in mild-to-moderate infections or at early stages in the clinical course, prior to severe disease progression.

Our findings corroborate several previous lines of evidence^{19-21,31} suggesting a relationship exists between pneumococci and SARS-CoV-2 infection among adults. Whereas IPD incidence declined precipitously during the early COVID-19 pandemic, this pattern may have been driven, in part, by frequent antibiotic treatment of COVID-19 patients who would otherwise be at risk,¹⁷ absent transmission of other viruses. Of note, non-bacteremic pneumococcal pneumonia and LRTI have persisted during the pandemic, and pneumococcal

antigen detection has been associated with increased disease severity among hospitalized COVID-19 cases.¹⁸

Increased density may facilitate pneumococcal transmission during SARS-CoV-2 infection in addition to increasing individuals' risk of subsequent LRTI and IPD, absent antibiotic treatment.^{38,39} Monitoring for severe co-infections involving SARS-CoV-2 and pneumococcus thus remains warranted as antimicrobial stewardship for COVID-19 cases improves. While vaccines now offer a primary prevention strategy for COVID-19, our results pinpoint interactions involving pneumococci in the upper airway as a component of SARS-CoV-2 natural history, resembling observations with other viruses. These findings may inform control strategies against polymicrobial infections.

FUNDING

The study was supported by the Innovative Genomics Institute at the University of California, Berkeley; Pfizer, Inc. (grant 61775823 to JAL); and the National Institutes of Health (grants R24ES028529 and R24ESD30888 to NH).

CONFLICTS OF INTEREST

JAL discloses receipt of grant funding and consulting honoraria from Pfizer, Inc.; grant funding and consulting honoraria from Merck, Sharp & Dohme; and consulting honoraria from VaxCytte, Inc.

REFERENCES

1. Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. *PLOS Medicine*, **2015**; 12:e1001776.
2. Walter ND, Taylor TH, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. *Clin Infect Dis*, **2010**; 50:175–83.

3. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis*, **2008**; 198: 962–70.
4. Karppinen S, Teräsjärvi J, Auranen K, et al. Acquisition and transmission of *Streptococcus pneumoniae* are facilitated during rhinovirus infection in families with children. *Am J Respir Crit Care Med*, **2017**; 196:1172–80.
5. Thors V, Christensen H, Morales-Aza B, et al. High-density bacterial nasal carriage in children is transient and associated with respiratory viral infections: implications for transmission dynamics. *Pediatr Infect Dis J*, **2019**; 38:533–8.
6. De Steenhuijsen P, Pitsers WAA, Heinonen S, Hasrat R, et al. Nasopharyngeal microbiota, host transcriptome, and disease severity in children with respiratory syncytial virus infection. *Am J Respir Crit Care Med*, **2016**; 194: 1104–15.
7. Baggett HC, Watson NL, Deloria Knoll M, et al. Density of upper respiratory colonization with *Streptococcus pneumoniae* and its role in the diagnosis of pneumococcal pneumonia among children aged <5 years in the PERCH study. *Clin Infect Dis*, **2017**; 64:S317–27.
8. DeMuri GP, Gern JE, Eickhoff JC, Lynch SV, Wald ER. Dynamics of bacterial colonization with *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* during symptomatic and asymptomatic viral upper respiratory tract infection. *Clin Infect Dis*, **2018**; 66:1045–53.
9. Miellet WR, van Veldhuizen J, Nicolaie MA, et al. Influenza-like illness exacerbates pneumococcal carriage in older adults. *Clin Infect Dis*, **2021**; 73:e2680–9.
10. Park DE, Higdon MM, Prospero C, et al. Upper respiratory tract co-detection of human endemic coronaviruses and high-density pneumococcus associated with increased severity among HIV-uninfected children under 5 years old in the PERCH Study. *Pediatr Infect Dis J*, **2021**; 40:503–12.
11. De Lastours V, Malosh R, Ramadugu K, et al. Co-colonization by *Streptococcus pneumoniae* and *Staphylococcus aureus* in the throat during acute respiratory illnesses. *Epidemiol Infect*, **2016**; 144:3507–19.
12. Mina MJ, McCullers JA, Klugman KP. Live attenuated influenza vaccine enhances colonization of *Streptococcus pneumoniae* and *Staphylococcus aureus* in mice. *mBio*, **2014**; 5:e01040-13.

13. Carniel BF, Marcon F, Rylance J, et al. Pneumococcal colonization impairs mucosal immune responses to live attenuated influenza vaccine. *JCI Insight*, **2021**; 6:141088.
14. Rylance J, de Steenhuijsen Piters WAA, Mina MJ, et al. Two randomized trials of the effect of live attenuated influenza vaccine on pneumococcal colonization. *Am J Respir Crit Care Med*, **2019**; 199:1160–3.
15. Howard LM, Zhu Y, Griffin MR, et al. Nasopharyngeal pneumococcal density during asymptomatic respiratory virus infection and risk for subsequent acute respiratory illness. *Emerg Infect Dis*, **2019**; 25:2040–7.
16. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. *J Infect*, **2020**; 81:266–75.
17. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol Infect*, **2021**; 27:520–31.
18. Watkins AE, Glick LR, Ott IM, et al. Detection of pneumococcus during hospitalization for SARS-CoV-2. medRxiv, **2022**; doi:10.1101/2022.07.13.22277607.
19. Mitsi E, Reiné J, Urban BC, et al. *Streptococcus pneumoniae* colonization associates with impaired adaptive immune responses against SARS-CoV-2. *J Clin Invest*, **2022**; 132:e157124.
20. Amin-Chowdhury Z, Aiano F, Mensah A, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): prospective national cohort study, England. *Clin Infect Dis*, **2021**; 72:e65–75.
21. Lewnard JA, Bruxvoort KJ, Fischer H, et al. Prevention of coronavirus disease 2019 among older adults receiving pneumococcal conjugate vaccine suggests interactions between *Streptococcus pneumoniae* and severe acute respiratory syndrome coronavirus 2 in the respiratory tract. *J Infect Dis*, **2022**; 225:1710–20.
22. Madhi SA, Klugman KP, Vaccine Trialist Group. A role for *Streptococcus pneumoniae* in virus-associated pneumonia. *Nat Med*, **2004**; 10:811–3.
23. Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. *J Infect Dis*, **2006**; 193:1236–43.

24. Nunes MC, Cutland CL, Klugman KP, Madhi SA. Pneumococcal conjugate vaccine protection against coronavirus-associated pneumonia hospitalization in children living with and without HIV. *mBio*, **2021**; 12:e02347-20.
25. Lewnard JA, Bruxvoort KJ, Hong VX, et al. Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study. *J Infect Dis*, **2022**; doi:10.1093/infdis/jiac098.
26. Lewnard JA, Mora AM, Nkwocha O, et al. Prevalence and clinical profile of severe acute respiratory syndrome coronavirus 2 infection among farmworkers, California, USA, June–November 2020. *Emerg Infect Dis*, **2021**; 27:1330–42.
27. Mora AM, Lewnard JA, Kogut K, et al. Risk factors associated with SARS-CoV-2 infection among farmworkers in Monterey County, California. *JAMA Netw Open*, **2021**; 4:e2124116.
28. Mora AM, Lewnard JA, Rauch S, et al. Impact of COVID-19 pandemic on California Farmworkers' mental health and food security. *J Agromedicine*, **2022**; 27:303–14.
29. Villarejo D, Wadsworth G. Farmworker housing study and action plan for Salinas Valley and Pajaro Valley. Available from: <https://www.co.monterey.ca.us/home/showdocument?id=63729>. Accessed 4 October, 2022.
30. Wyllie AL, Rümke LW, Arp K, et al. Molecular surveillance on *Streptococcus pneumoniae* carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children. *Sci Rep*, **2016**; 6:34888.
31. Barman TK, Singh AK, Bonin JL, Nafiz TN, Salmon SL, Metzger DW. Lethal synergy between SARS-CoV-2 and *Streptococcus pneumoniae* in hACE2 mice and protective efficacy of vaccination. *JCI Insight*, **2022**; 7:e159422.
32. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*, **2021**; 2:e13–22.
33. Almeida ST, Paulo AC, Froes F, de Lencastre H, Sá-Leão R. Dynamics of pneumococcal carriage in adults: a new look at an old paradigm. *J Infect Dis*, **2021**; 223:1590–600.

34. Morpeth SC, Munywoki P, Hammitt LL, et al. Impact of viral upper respiratory tract infection on the concentration of nasopharyngeal pneumococcal carriage among Kenyan children. *Sci Rep*, **2018**; 8:11030.
35. Jochems SP, Marcon F, Carniel BF, et al. Inflammation induced by influenza virus impairs human innate immune control of pneumococcus. *Nat Immunol*, **2018**; 19:1299–308.
36. Nikolaou E, Jochems SP, Mitsi E, et al. Experimental human challenge defines distinct pneumococcal kinetic profiles and mucosal responses between colonized and non-colonized adults. *mBio*, **2021**; 12:e02020-20.
37. Wyllie AL, Chu MLJN, Schellens MHB, et al. *Streptococcus pneumoniae* in saliva of Dutch primary school children. *PLoS One*, **2014**; 9:e102045.
38. Wolter N, Tempia S, Cohen C, et al. High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia. *Clin Infect Dis*, **2014**; 210:1649–57.
39. Weinberger DM, Grant LR, Steiner CA, et al. Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. *Clin Infect Dis*, **2014**; 58:188–94.

Table 1: Co-detection of SARS-CoV-2 and pneumococcus within the primary and expanded study populations.

Pneumococcal detection threshold	Population	SARS-CoV-2 infected/Total, n (%)					
		All testing venues		Clinic-based testing		Outreach-based testing	
		<u>Pneumococcus detected</u>	<u>Pneumococcus not detected</u>	<u>Pneumococcus detected</u>	<u>Pneumococcus not detected</u>	<u>Pneumococcus detected</u>	<u>Pneumococcus not detected</u>
<i>lytA</i> C _T <40 and <i>piaB</i> C _T <40	Primary study participants	27/103 (26.2)	102/992 (10.3)	25/60 (41.7)	69/489 (14.1)	2/43 (4.7)	33/503 (6.6)
	Expanded dataset, including pneumococcal sub-study participants	32/117 (27.4)	112/1,161 (9.6)	26/63 (41.3)	69/501 (13.8)	6/54 (11.1)	43/660 (6.5)
<i>lytA</i> C _T <35 and <i>piaB</i> C _T <35	Primary study participants	16/47 (34.0)	113/1,048 (10.8)	15/30 (50.0)	79/519 (15.2)	1/17 (5.9)	34/529 (6.4)
	Expanded dataset, including pneumococcal sub-study participants	19/53 (35.8)	125/1,225 (10.2)	16/31 (51.6)	79/533 (14.8)	3/22 (13.6)	46/692 (6.6)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

Table 2: SARS-CoV-2 infection within the primary study population, by pneumococcal carriage status.

Attribute		n/N (%)					
		All testing venues		Clinic-based testing		Outreach-based testing	
		Pneumococcus detected	Pneumococcus not detected	Pneumococcus detected	Pneumococcus not detected	Pneumococcus detected	Pneumococcus not detected
Age	18-29 years	6/29 (20.7)	27/243 (11.1)	5/16 (31.2)	16/120 (13.3)	1/13 (7.7)	11/123 (8.9)
	30-39 years	10/37 (27.0)	22/234 (9.4)	10/22 (45.5)	15/112 (13.4)	0/15 (0.0)	7/122 (5.7)
	40-49 years	9/26 (34.6)	33/263 (12.5)	8/16 (50.0)	23/140 (16.4)	1/10 (10.0)	10/123 (8.1)
	≥50 years	2/11 (18.2)	20/252 (7.9)	2/6 (33.3)	15/117 (12.8)	0/5 (0.0)	5/135 (3.7)
Sex	Male	12/45 (26.7)	50/477 (10.5)	12/26 (46.2)	35/230 (15.2)	0/19 (0.0)	15/247 (6.1)
	Female	15/58 (25.9)	52/515 (10.1)	13/34 (38.2)	34/259 (13.1)	2/24 (8.3)	18/256 (7.0)
Language spoken at home	Spanish	15/68 (22.1)	88/863 (10.2)	14/35 (40.0)	57/411 (13.9)	1/33 (3.0)	31/452 (6.9)
	Indigenous language	11/29 (37.9)	13/79 (16.5)	11/23 (47.8)	12/60 (20.0)	0/6 (0.0)	1/19 (5.3)
	English	1/6 (16.7)	1/50 (2.0)	0/2 (0.0)	0/18 (0.0)	1/4 (25.0)	1/32 (3.1)
Country of birth	Mexico	24/87 (27.6)	86/826 (10.4)	23/52 (44.2)	59/422 (14.0)	1/35 (2.9)	27/404 (6.7)
	United States	2/13 (15.4)	11/127 (8.7)	1/5 (20.0)	5/42 (11.9)	1/8 (12.5)	6/85 (7.1)
	Other	1/3 (33.3)	5/39 (12.8)	1/3 (33.3)	5/25 (20.0)	0/0	0/14 (0.0)
Community of residence	Salinas	6/39 (15.4)	43/443 (9.7)	4/21 (19.0)	26/234 (11.1)	2/18 (11.1)	17/209 (8.1)
	Greenfield	17/38 (44.7)	38/270 (14.1)	17/28 (60.7)	35/182 (19.2)	0/10 (0.0)	3/88 (3.4)
	Other	4/26 (15.4)	21/279 (7.5)	4/11 (36.4)	8/73 (11.0)	0/15 (0.0)	13/206 (6.3)
Household crowding	0-2 persons/bedroom	12/53 (22.6)	64/642 (10.0)	11/30 (36.7)	42/296 (14.2)	1/23 (4.3)	22/346 (6.4)
	2.1 to 4 persons/bedroom	11/40 (27.5)	33/320 (10.3)	10/22 (45.5)	24/178 (13.5)	1/18 (5.6)	9/142 (6.3)
	>4 persons/bedroom	4/8 (50.0)	5/29 (17.2)	4/6 (66.7)	3/15 (20.0)	0/2 (0.0)	2/14 (14.3)
Exposure to children at home	No children at home	4/18 (22.2)	29/258 (11.2)	4/7 (57.1)	20/116 (17.2)	0/11 (0.0)	9/142 (6.3)
	Any child <5 years old	10/45 (22.2)	33/361 (9.1)	9/27 (33.3)	20/187 (10.7)	1/18 (5.6)	13/174 (7.5)
	Children 5-18 years old only	13/40 (32.5)	40/373 (10.7)	12/26 (46.2)	29/186 (15.6)	1/14 (7.1)	11/187 (5.9)
Household income	<\$25,000	14/53 (26.4)	55/494 (11.1)	14/33 (42.4)	37/249 (14.9)	0/20 (0.0)	18/245 (7.3)
	\$25,000-34,999	6/21 (28.6)	16/236 (6.8)	5/11 (45.5)	9/98 (9.2)	1/10 (10.0)	7/138 (5.1)
	\$35,000-49,999	4/13 (30.8)	21/146 (14.4)	4/8 (50.0)	17/75 (22.7)	0/5 (0.0)	4/71 (5.6)
	≥\$50,000	1/3 (33.3)	7/73 (9.6)	0/1 (0.0)	4/45 (8.9)	1/2 (50.0)	3/28 (10.7)
Education level	No formal schooling	5/8 (62.5)	7/54 (13.0)	5/8 (62.5)	6/40 (15.0)	0/0	1/14 (7.1)
	Primary school complete	11/40 (27.5)	44/379 (11.6)	10/22 (45.5)	32/198 (16.2)	1/18 (5.6)	12/181 (6.6)
	Junior high school complete	7/43 (16.3)	30/330 (9.1)	7/24 (29.2)	22/158 (13.9)	0/19 (0.0)	8/172 (4.7)
	High school complete	4/12 (33.3)	21/228 (9.2)	3/6 (50.0)	9/92 (9.8)	1/6 (16.7)	12/136 (8.8)
Agricultural occupation	Fieldwork	25/88 (28.4)	80/728 (11.0)	24/51 (47.1)	54/355 (15.2)	1/37 (2.7)	26/373 (7.0)
	Non-fieldwork	1/14 (7.1)	20/255 (7.8)	0/8 (0.0)	13/125 (10.4)	1/6 (16.7)	7/130 (5.4)
Housing type	Single-family house	16/51 (31.4)	52/467 (11.1)	15/37 (40.5)	35/282 (12.4)	1/14 (7.1)	17/185 (9.2)
	Apartment	10/40 (25.0)	40/432 (9.3)	9/19 (47.4)	26/169 (15.4)	1/21 (4.8)	14/263 (5.3)
	Trailer/mobile home	0/5 (0.0)	3/38 (7.9)	0/3 (0.0)	2/20 (10.0)	0/2 (0.0)	1/18 (5.6)
	Hotel/motel	1/6 (16.7)	5/31 (16.1)	1/1 (100)	5/7 (71.4)	0/5 (0.0)	0/24 (0.0)
	Other	0/1 (0.0)	2/24 (8.3)	0/0	1/11 (9.1)	0/1 (0.0)	1/13 (7.7)
Body mass index	<25	3/14 (21.4)	16/182 (8.8)	3/5 (60.0)	12/101 (11.9)	0/9 (0.0)	4/81 (4.9)
	25 to <30 (overweight)	12/41 (29.3)	36/372 (9.7)	12/25 (48.0)	21/178 (11.8)	0/16 (0.0)	15/194 (7.7)
	≥30 (obese)	9/45 (20.0)	46/414 (11.1)	7/27 (25.9)	33/193 (17.1)	2/18 (11.1)	13/221 (5.9)

Cigarette smoking	Never smoked	22/87 (25.3)	87/800 (10.9)	20/50 (40.0)	58/394 (14.7)	2/37 (5.4)	29/406 (7.1)
	Former smoking	5/13 (38.5)	12/145 (8.3)	5/9 (55.6)	10/77 (13.0)	0/4 (0.0)	2/68 (2.9)
	Current smoking	0/3 (0.0)	3/46 (6.5)	0/1 (0.0)	1/17 (5.9)	0/2 (0.0)	2/29 (6.9)
COVID-19 risk-mitigating behaviors	Mask wearing indoors	27/95 (28.4)	98/914 (10.7)	25/56 (44.6)	66/449 (14.7)	2/39 (5.1)	32/465 (6.9)
	Avoidance of indoor social gatherings in prior 2 weeks	25/98 (25.5)	93/935 (9.9)	23/57 (40.4)	65/462 (14.1)	2/41 (4.9)	28/473 (5.9)
	Regular handwashing	26/97 (26.8)	100/965 (10.4)	24/57 (42.1)	67/474 (14.1)	2/40 (5.0)	33/491 (6.7)
Clinical status	Any symptoms in prior 2 weeks	16/30 (53.3)	59/261 (22.6)	15/23 (65.2)	45/167 (26.9)	1/7 (14.3)	14/94 (14.9)
	No symptoms in prior 2 weeks	11/72 (15.3)	43/726 (5.9)	10/36 (27.8)	24/317 (7.6)	1/36 (2.8)	19/409 (4.6)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets. Data may not add to column totals in case of missing data on any question.

Table 3: Association of SARS-CoV-2 infection with pneumococcal carriage detection within the primary study population.

Participants	All testing venues		Clinic-based testing		Outreach-based testing	
	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Total sample	2.94 (1.79, 4.81)	2.73 (1.58, 4.69)	4.33 (2.45, 7.68)	4.01 (2.08, 7.75)	0.69 (0.16, 3.06)	0.95 (0.20, 4.44)
Any symptoms in prior two weeks	3.54 (1.62, 7.79)	3.38 (1.35, 8.40)	4.86 (1.95, 12.2)	6.12 (1.87, 20.5)	--	--
No symptoms in prior two weeks	2.74 (1.35, 5.62)	2.79 (1.26, 6.24)	4.61 (2.01, 10.7)	5.63 (1.91, 16.2)	0.58 (0.08, 4.53)	0.78 (0.09, 6.65)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio; CI: confidence interval. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

Table 4: Association of SARS-CoV-2 infection with *lytA* and *piaB*C_T values in culture-enriched saliva.

qPCR target	Carriage status and Ct value for indicated qPCR target	SARS-CoV-2 infected/Total, %		Odds ratio (95% CI), computed within the primary study population	
		Primary study participants	Expanded dataset, including pneumococcal sub-study participants	Unadjusted	Adjusted
<i>lytA</i>	No pneumococcal carriage	102/992 (10.3)	112/1,161 (9.6)	ref.	ref.
	35-39.9 (with <i>piaB</i> C _T <40)	5/17 (29.4)	6/21 (28.6)	3.66 (1.23, 10.8)	2.88 (0.86, 9.74)
	30-34.9 (with <i>piaB</i> C _T <40)	7/31 (22.6)	7/32 (21.9)	2.33 (0.96, 5.63)	2.26 (0.88, 5.84)
	<30 (with <i>piaB</i> C _T <40)	15/55 (27.3)	19/64 (29.7)	3.11 (1.64, 5.88)	2.95 (1.47, 5.92)
<i>piaB</i>	Continuous OR—per 1-unit decrease in <i>lytA</i> C _T , among pneumococcal carriers	27/103 (26.2)	32/117 (27.4)	0.97 (0.88, 1.07)	0.94 (0.81, 1.09)
	No pneumococcal carriage	102/992 (10.3)	112/1,161 (9.6)	ref.	ref.
	35-39.9 (with <i>lytA</i> C _T <40)	11/52 (21.2)	13/58 (22.4)	2.24 (1.10, 4.58)	1.73 (0.80, 3.74)
	30-34.9 (with <i>lytA</i> C _T <40)	8/30 (26.7)	9/33 (27.3)	2.94 (1.26, 6.90)	3.38 (1.35, 8.40)
	<30 (with <i>lytA</i> C _T <40)	8/21 (38.1)	10/26 (38.5)	5.03 (1.98, 12.8)	5.77 (2.06, 16.4)
	Continuous OR—per 1-unit decrease in <i>piaB</i> C _T , among pneumococcal carriers	27/103 (26.2)	32/117 (27.4)	1.07 (0.96, 1.19)	1.24 (1.00, 1.55)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio; CI: confidence interval. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

Table 5: Association of SARS-CoV-2 infection with recent exposure among individuals carrying and those not carrying pneumococcus.

Exposure status	SARS-CoV-2 infected/Total (%), by pneumococcal carriage status		Pneumococcal carriage not detected		Pneumococcal carriage detected	
	Pneumococcus detected	Pneumococcus not detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
No contact with symptomatic individual in prior two weeks	15/78 (19.2)	61/769 (7.9)	ref.	ref.	ref.	ref.
Contact with symptomatic individual in prior two weeks—Any	9/13 (69.2)	30/115 (26.1)	3.21 (1.95, 5.26)	3.29 (1.94, 5.59)	7.25 (1.95, 26.8)	7.64 (1.91, 30.7)
Contact with symptomatic individual in prior two weeks—Home	6/9 (66.7)	18/61 (29.5)	3.82 (2.10, 6.99)	3.99 (2.06, 7.67)	5.35 (1.22, 24.0)	6.66 (1.32, 33.0)
Contact with symptomatic individual in prior two weeks—Work	5/7 (71.4)	16/63 (25.4)	2.49 (1.33, 4.63)	2.26 (1.17, 4.38)	6.34 (1.14, 34.8)	6.25 (1.00, 38.0)
No notification of contact with confirmed case in prior two weeks	25/98 (25.5)	94/922 (10.2)	ref.	ref.	ref.	ref.
Notification of contact with confirmed case in prior two weeks	2/5 (40.0)	8/70 (11.4)	0.90 (0.42, 1.98)	0.83 (0.37, 1.85)	2.51 (0.37, 17.1)	2.14 (0.28, 16.0)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio; CI: confidence interval. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

Text S1: Supplemental laboratory methods.

Culture enrichment and bacterial DNA extraction. Raw saliva specimens were frozen at -20°C after collection and thereafter stored at -80°C . Samples were thawed on ice after arrival at the laboratory; after thawing, $100\mu\text{L}$ of unprocessed saliva was spread onto trypticase soy agar supplemented with 7% sheep's blood and 5mg/L gentamicin. Plates were then incubated at 37°C with 5% CO_2 for 14-19 hours. Bacterial growth was harvested into 2.1mL of 10% glycerol brain-heart infusion broth (BHI), and stored at -20°C . Specimen DNA was extracted from $200\mu\text{L}$ of the culture-enriched sample after being thawed, vortexed, and transferred to sterile 1.5mL Eppendorf tubes prefilled with freshly prepared lysis buffer (40mg/mL lysozyme and 75U/mol mutanolysin) for 90 minutes' incubation at 37°C . Next, $20\mu\text{L}$ of protease K was added to each sample, followed by incubation for 60 minutes at 56°C . Subsequent extraction steps used the QIAGEN DNeasy Blood and Tissue Kit (QIAGEN; Hilden, Germany) following manufacturer's instructions. Briefly, DNA was eluted into $50\mu\text{L}$ elution buffer and stored at -20°C ; samples with DNA concentration $<20\text{ng}/\mu\text{L}$, measured using a spectrophotometer, underwent a second extraction. Positive and negative control DNA was extracted from pure cultures of *S. pneumoniae* by the boilate method. Briefly, colonies grown overnight on a TSA-GENT plate were extracted and suspended in $60\mu\text{L}$ nuclease-free water, then placed into a water bath heated to 100°C . Samples were boiled for 10 minutes before being centrifuged for 10 minutes at 14,000 rpm. Nucleic acid concentration was measured using a spectrophotometer following removal of the supernatant. Control DNA was diluted with nuclease-free water to a concentration of $50\text{ng}/\mu\text{L}$.

Detection of *lytA* and *piaB* in culture-enriched specimens. Positive control samples used a diluted series of the reference strain ATCC 49619, while negative controls were DNA from human saliva previously characterized as negative for *S. pneumoniae*, and DNA from *E. coli* reference strain ATCC 25922. Gene detection via qPCR was conducted with primer concentrations at 400nM and 300nM, and probe concentrations at 75nM and 200nM, for *lytA* and *piaB*, respectively. All qPCR assays tested $2.5\mu\text{L}$ of DNA template in $25\mu\text{L}$ reactions. Thermal cycling conditions were as follows: 3 minutes at 95°C for initial denaturation; 15 seconds at 98°C for denaturation; and 30 seconds at 60°C for annealing.

Detection of SARS-CoV-2 in saliva samples. Prior to measuring C_T values, all samples were subjected to a freeze-thaw cycle for aliquoting. In addition, saliva samples from participants with a positive diagnostic test result were heat inactivated at 56°C for 30 minutes for safety purposes. Saliva samples were defrosted on ice for approximately 30 minutes. Once defrosted, raw saliva was pipetted into Omnigene tubes (Omnigene OM-505) and an equal volume of Omnigene solution was added. Samples were then extracted as previously described.¹ Briefly, samples were incubated at 50°C for 2 hours, followed by 30 minutes' incubation at 65°C . Using a Hamilton Microlab STARlet, $112\mu\text{L}$ of processed saliva was combined with $338\mu\text{L}$ of 2x DNA/RNA Shield (Zymo; R1200). RNA was extracted with the MagMax Viral Pathogen Kit (ThermoFisher; A42352) using a Hamilton Vantage. Viral N and E genes, and human RNaseP were amplified using the LuNER assay, as previously described.² Positive and negative controls were included for extraction and qPCR and were used to establish plate validity. RNaseP amplification within each sample was used to determine sample validity. Samples were re-extracted and re-amplified as needed for final C_T values.

Supplemental references:

1. Hamilton JR, Stah EC, Tsuchida CA, et al. Robotic RNA extraction for SARS-CoV-2 surveillance using saliva samples. *PLOS ONE* 2021; doi:10.1371/journal.pone.02555690.
2. Stahl EC, Tsuchida CA, Hamilton JR, et al. IGI-LuNER: single-well multiplexed RT-qPCR test for SARS-CoV-2. *medRxiv* 2020; doi:10.1101/2020.12.10.20247338.

Table S1: Gene targets for molecular detection of pneumococci.

Gene	Nucleotide sequence
<i>lytA</i>	ACGCAATCTAGCAGATGAAGCAGGTTTGCCGAAAACGCTTGATACAGGGAGTTTAGCTGGAATTAACGCACGA
<i>piaB</i>	CATTGGTGGCTTAGTAAGTGCAATTTTGTATACGCGATTGCTGTAAGCGGAAAAGCAGGCCTTACCCCTATAAACTTGCCTTATCAG GAACTTGTGTTAGTA

Table S2: Characteristics of the primary study population, by pneumococcal carriage status.

Attribute	n/N (%)						
	Total sample		Clinic sample		Outreach sample		
	<u>Pneumococcus detected</u> N=103	<u>Pneumococcus not detected</u> N=992	<u>Pneumococcus detected</u> N=60	<u>Pneumococcus not detected</u> N=489	<u>Pneumococcus detected</u> N=43	<u>Pneumococcus not detected</u> N=503	
Age							
	18-29 years	29 (28.2)	243 (24.5)	16 (26.7)	120 (24.5)	13 (30.2)	123 (24.5)
	30-39 years	37 (35.9)	234 (23.6)	22 (36.7)	112 (22.9)	15 (34.9)	122 (24.3)
	40-49 years	26 (25.2)	263 (26.5)	16 (26.7)	140 (28.6)	10 (23.3)	123 (24.5)
	≥50 years	11 (10.7)	252 (25.4)	6 (10.0)	117 (23.9)	5 (11.6)	135 (26.8)
Sex							
	Male	45 (43.7)	477 (48.1)	26 (43.3)	230 (47.0)	19 (44.2)	247 (49.1)
	Female	58 (56.3)	515 (51.9)	34 (56.7)	259 (53.0)	24 (55.8)	256 (50.9)
Language spoken at home							
	Spanish	68 (66.0)	863 (87.0)	35 (58.3)	411 (84.0)	33 (76.7)	452 (89.9)
	Indigenous language	29 (28.2)	78 (8.0)	23 (38.3)	60 (12.3)	6 (14.0)	19 (3.8)
	English	6 (5.8)	50 (5.0)	2 (3.3)	18 (3.7)	4 (9.3)	32 (6.4)
Country of birth							
	Mexico	87 (84.5)	826 (83.3)	52 (86.7)	422 (86.3)	35 (81.4)	404 (80.3)
	United States	13 (12.6)	127 (12.8)	5 (8.3)	42 (8.6)	8 (18.6)	85 (16.9)
	Other	3 (2.9)	39 (3.9)	3 (5.0)	25 (5.1)	0 (0.0)	14 (2.8)
Community of residence							
	Salinas	39 (37.9)	443 (44.7)	21 (35.0)	234 (47.9)	18 (41.9)	209 (41.6)
	Greenfield	38 (36.9)	270 (27.2)	28 (46.7)	182 (37.2)	10 (23.3)	88 (17.5)
	Other	26 (25.2)	279 (28.1)	11 (18.3)	73 (14.9)	15 (34.9)	206 (41.0)
Household crowding							
	0-2 persons/bedroom	53 (52.5)	642 (64.8)	30 (51.7)	296 (60.5)	23 (53.5)	346 (68.9)
	2.1 to 4 persons/bedroom	40 (39.6)	320 (32.3)	22 (37.9)	178 (36.4)	18 (41.9)	142 (28.3)
	>4 persons/bedroom	8 (7.9)	29 (2.9)	6 (10.3)	15 (3.1)	2 (4.7)	14 (2.8)
Exposure to children at home							
	No children at home	18 (17.5)	258 (26.0)	7 (11.7)	116 (23.7)	11 (25.6)	142 (28.2)
	Any child <5 years old	45 (43.7)	361 (36.4)	27 (45.0)	187 (38.2)	18 (41.9)	174 (34.6)
	Children 5-18 years old only	40 (38.8)	373 (37.6)	26 (43.3)	186 (38.0)	314 (32.6)	187 (37.2)
Household income							
	<\$25,000	53 (51.5)	494 (49.8)	33 (55.0)	249 (50.9)	20 (46.5)	245 (48.7)
	\$25,000-34,999	21 (20.4)	236 (23.8)	11 (18.3)	98 (20.0)	10 (23.3)	138 (27.4)
	\$35,000-49,999	13 (12.6)	146 (14.7)	8 (13.3)	75 (15.3)	5 (11.6)	71 (14.1)
	≥\$50,000	3 (2.9)	73 (7.4)	1 (1.7)	45 (9.2)	2 (4.7)	28 (5.6)
Education level							
	No formal schooling	8 (7.8)	54 (5.4)	8 (13.3)	40 (8.2)	0 (0.0)	14 (2.8)
	Primary school complete	40 (38.8)	379 (38.2)	22 (36.7)	198 (40.6)	18 (41.9)	181 (36.0)
	Junior high school complete	43 (41.7)	330 (33.3)	24 (40.0)	158 (32.4)	19 (44.2)	172 (34.2)
	High school complete	12 (11.7)	228 (23.0)	6 (10.0)	92 (18.9)	6 (14.0)	136 (27.0)
Agricultural occupation							
	Fieldwork	88 (86.3)	728 (74.1)	51 (86.4)	355 (74.0)	37 (86.0)	373 (74.2)
	Non-fieldwork	14 (13.7)	255 (25.9)	8 (13.6)	125 (26.0)	6 (14.0)	130 (25.8)
Housing type							
	Single-family house	51 (49.5)	467 (47.1)	37 (61.7)	582 (57.7)	14 (32.6)	185 (36.8)
	Apartment	40 (38.8)	432 (43.5)	19 (31.7)	169 (34.6)	21 (48.8)	263 (52.3)
	Trailer/mobile home	5 (4.9)	38 (3.8)	3 (5.0)	20 (4.1)	2 (4.7)	18 (3.6)
	Hotel/motel	6 (5.8)	31 (3.1)	1 (1.7)	7 (1.4)	5 (11.6)	24 (4.8)
	Other						
Body mass index							
	<25	14 (14.0)	182 (18.8)	5 (8.8)	101 (21.4)	9 (20.9)	81 (16.3)
	25 to <30 (overweight)	41 (41.0)	372 (38.4)	25 (43.9)	178 (37.7)	16 (37.2)	194 (39.1)

Cigarette smoking	≥30 (obese)	45 (45.0)	414 (42.8)	27 (47.4)	193 (40.9)	18 (41.9)	221 (44.6)
	Never smoked	87 (84.5)	800 (80.7)	50 (83.3)	394 (80.7)	37 (86.0)	406 (80.7)
	Former smoking	13 (12.6)	145 (14.6)	9 (15.0)	77 (15.8)	4 (9.3)	68 (13.5)
COVID-19 risk behaviors	Current smoking	3 (2.9)	46 (4.6)	1 (1.7)	17 (3.5)	2 (4.7)	29 (5.8)
	Inconsistent mask wearing indoors	8 (7.8)	78 (7.9)	4 (6.7)	40 (8.2)	4 (9.3)	38 (7.6)
	Indoor social gathering in prior 2 weeks	5 (4.9)	55 (5.6)	3 (5.0)	26 (5.3)	2 (4.7)	29 (5.8)
Clinical status	Lack of regular handwashing	6 (5.8)	27 (2.7)	3 (5.0)	15 (3.1)	3 (7.0)	12 (2.4)
	Current SARS-CoV-2 infection	27 (26.2)	102 (10.3)	25 (41.7)	69 (14.1)	2 (4.7)	33 (6.6)
	Any symptoms in prior 2 weeks	30 (29.4)	261 (26.4)	23 (39.0)	167 (34.5)	7 (16.3)	94 (18.7)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

Table S3: Characteristics of the pneumococcal sub-study population, by pneumococcal carriage status.

Attribute ¹	n/N (%)						
	Total sample		Clinic sample		Outreach sample		
	<u>Pneumococcus detected</u>	<u>Pneumococcus not detected</u>	<u>Pneumococcus detected</u>	<u>Pneumococcus not detected</u>	<u>Pneumococcus detected</u>	<u>Pneumococcus not detected</u>	
	N=14	N=169	N=3	N=12	N=11	N=157	
Age	18-29 years	4 (28.6)	66 (39.1)	1 (33.3)	7 (58.3)	3 (27.3)	59 (37.6)
	30-39 years	3 (21.4)	30 (17.8)	0 (0.0)	2 (16.7)	3 (27.3)	28 (17.8)
	40-49 years	2 (14.3)	35 (20.7)	1 (33.3)	1 (8.3)	1 (9.1)	34 (21.7)
	≥50 years	5 (35.7)	38 (22.5)	1 (33.3)	2 (16.7)	4 (36.4)	36 (22.9)
Sex	Male	6 (42.9)	56 (33.1)	1 (33.3)	4 (33.3)	5 (45.5)	52 (33.1)
	Female	8 (57.1)	113 (66.9)	2 (66.7)	8 (66.7)	6 (54.5)	105 (66.9)
Language spoken at home	Spanish	8 (57.1)	112 (66.3)	2 (66.7)	7 (58.3)	6 (54.5)	105 (66.9)
	Indigenous language	0 (0.0)	1 (0.6)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)
	English	6 (42.9)	56 (33.1)	1 (33.3)	4 (33.3)	5 (45.5)	52 (33.1)
Country of birth	Mexico	6 (42.9)	88 (52.1)	2 (66.7)	6 (50.0)	4 (36.4)	82 (52.2)
	United States	7 (50.0)	79 (46.7)	1 (33.3)	6 (50.0)	6 (54.5)	73 (46.5)
	Other	1 (7.1)	2 (1.2)	0 (0.0)	0 (0.0)	1 (9.1)	2 (1.3)
Household crowding	0-2 persons/bedroom	12 (85.7)	145 (85.8)	3 (100)	7 (58.3)	9 (81.8)	138 (87.9)
	2.1 to 4 persons/bedroom	2 (14.3)	22 (13.0)	0 (0.0)	5 (41.7)	2 (18.2)	17 (10.8)
	>4 persons/bedroom	0 (0.0)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.3)
Exposure to children at home	No children at home	3 (21.4)	57 (33.7)	1 (33.3)	5 (41.7)	2 (18.2)	52 (33.1)
	Any child <5 years old	4 (28.6)	49 (29.0)	0 (0.0)	6 (50.0)	4 (36.4)	43 (27.4)
	Children 5-18 years old only	7 (50.0)	63 (37.3)	2 (66.7)	21 (8.3)	5 (45.5)	62 (39.5)
Household income	<\$25,000	3 (25.0)	68 (43.6)	1 (50.0)	1 (9.1)	2 (20.0)	67 (46.2)
	\$25,000-34,999	3 (25.0)	24 (15.4)	0 (0.0)	4 (36.4)	3 (30.0)	20 (13.8)
	\$35,000-49,999	5 (41.7)	30 (19.2)	1 (50.0)	4 (36.4)	4 (40.0)	26 (17.9)
	≥\$50,000	1 (8.3)	34 (21.8)	0 (0.0)	2 (18.2)	1 (10.0)	32 (22.1)
Education level	No formal schooling	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Primary school complete	3 (21.4)	35 (20.7)	1 (33.3)	3 (25.0)	2 (18.2)	32 (20.4)
	Junior high school complete	2 (14.3)	23 (13.6)	0 (0.0)	0 (0.0)	2 (18.2)	23 (14.6)
	High school complete	9 (64.3)	110 (65.1)	2 (66.7)	9 (75.0)	7 (63.6)	101 (64.3)
Housing type	Single-family house	4 (28.6)	73 (43.2)	3 (100.0)	6 (50.0)	1 (9.1)	67 (42.7)
	Apartment	10 (71.4)	91 (53.8)	0 (0.0)	5 (41.7)	10 (90.9)	86 (54.8)
	Trailer/mobile home	0 (0.0)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.3)
	Hotel/motel	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Other	0 (0.0)	2 (1.2)	0 (0.0)	1 (8.3)	0 (0.0)	1 (0.6)
Clinical status	Current SARS-CoV-2 infection	5 (35.7)	10 (5.9)	1 (33.3)	0 (0.0)	4 (36.4)	10 (6.4)
	Any symptoms in prior 2 weeks	7 (50.0)	82 (48.5)	3 (100)	6 (50.0)	4 (36.4)	76 (48.4)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

¹Abbreviated interviews with participants in the pneumococcal sub-study collected data on a reduced set of questions.

Table S4: Association of SARS-CoV-2 infection with *lytA* detection in *piaB*-negative specimens.

Sample	Participants	SARS-CoV-2 infected/Total (%)			
		<i>lytA</i> detected	<i>lytA</i> not detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI) ¹
Total sample	Primary study participants	28/193 (14.5)	74/793 (9.3)	1.63 (1.02, 2.61)	1.57 (0.96, 2.57)
	Expanded dataset, including pneumococcal sub-study participants	29/218 (13.3)	83/937 (8.9)	1.55 (0.98, 2.44)	--
Clinic-based sample	Primary study participants	23/99 (23.2)	46/387 (11.9)	2.24 (1.29, 3.91)	1.95 (1.07, 3.56)
	Expanded dataset, including pneumococcal sub-study participants	23/100 (23.0)	46/398 (11.6)	2.28 (1.30, 3.98)	--
Outreach-based sample	Primary study participants	5/94 (5.3)	28/406 (6.9)	0.76 (0.29, 2.02)	0.77 (0.27, 2.18)
	Expanded dataset, including pneumococcal sub-study participants	6/118 (5.1)	37/539 (6.9)	0.73 (0.30, 1.76)	--

SARS nCoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Data are subset to specimens without *piaB* detection. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.

¹Adjusted odds ratios were not computed for analyses within the expanded dataset, as data were collected for a limited set of covariates among pneumococcal sub-study participants.

Table S5: Unadjusted associations of SARS-CoV-2 infection with pneumococcal carriage detection within the expanded study population, including participants in the primary study and pneumococcal sub-study.

Participants	All testing venues	Clinic-based testing	Outreach-based testing
	Unadjusted OR (95% CI)	Unadjusted OR (95% CI)	Unadjusted OR (95% CI)
Total sample	3.31 (2.08, 5.24)	4.40 (2.50, 7.72)	1.80 (0.73, 4.45)
Any symptoms in prior two weeks	4.15 (2.04, 8.42)	4.40 (1.87, 10.3)	3.64 (0.99, 13.4)
No symptoms in prior two weeks	3.01 (1.50, 6.01)	4.73 (2.04, 10.9)	1.16 (0.26, 5.13)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets.

Table S6: Association of clinical symptoms with pneumococcal carriage detection and SARS-CoV-2 infection.

Symptom	Symptom presence	Association with pneumococcal detection				Association with SARS-CoV-2 detection			
		Pneumococcus not detected	Pneumococcus detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	SARS-CoV-2 not detected	SARS-CoV-2 detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Dry cough	Symptom absent	1,087	105	ref.	ref.	1,083	109	ref.	ref.
	Symptom present	69	11	1.70 (0.83, 3.49)	1.44 (0.63, 3.29)	45	35	6.56 (3.81, 11.3)	7.10 (3.93, 12.9)
Productive cough	Symptom absent	1,095	106	ref.	ref.	1,082	119	ref.	ref.
	Symptom present	61	10	1.25 (0.57, 2.74)	1.01 (0.41, 2.44)	46	25	3.85 (2.20, 6.74)	4.34 (2.36, 7.99)
Pressure in ears	Symptom absent	1,136	109	ref.	ref.	1,112	133	ref.	ref.
	Symptom present	20	7	3.13 (1.19, 8.27)	2.64 (0.85, 8.27)	16	11	3.87 (1.60, 9.33)	2.82 (1.03, 7.61)
Blocked nose	Symptom absent	1,087	108	ref.	ref.	1,077	118	ref.	ref.
	Symptom present	69	8	0.97 (0.40, 2.35)	0.56 (0.20, 1.54)	51	26	3.32 (1.85, 5.97)	3.61 (1.90, 6.80)
Runny nose	Symptom absent	1,071	104	ref.	ref.	1,056	119	ref.	ref.
	Symptom present	85	12	1.10 (0.51, 2.41)	0.97 (0.41, 2.27)	72	25	2.85 (1.63, 4.96)	3.35 (1.86, 6.04)
Sneezing	Symptom absent	1,036	105	ref.	ref.	1,023	118	ref.	ref.
	Symptom present	120	11	0.63 (0.26, 1.49)	0.64 (0.25, 1.58)	105	26	1.77 (1.00, 3.11)	2.04 (1.13, 3.72)
Watery eyes	Symptom absent	1,084	111	ref.	ref.	1,069	126	ref.	ref.
	Symptom present	72	5	0.47 (0.14, 1.56)	0.40 (0.11, 1.39)	59	18	1.79 (0.92, 3.47)	1.80 (0.87, 3.70)
Hoarse voice	Symptom absent	1,109	109	ref.	ref.	1,094	124	ref.	ref.
	Symptom present	47	7	1.02 (0.39, 2.69)	0.82 (0.29, 2.32)	34	20	3.18 (1.66, 6.08)	3.43 (1.70, 6.95)
Fever	Symptom absent	1,109	102	ref.	ref.	1,101	110	ref.	ref.
	Symptom present	47	14	2.51 (1.23, 5.15)	1.79 (0.77, 4.24)	27	34	9.33 (5.13, 16.9)	10.3 (5.29, 20.1)
Sweating	Symptom absent	1,110	106	ref.	ref.	1,096	120	ref.	ref.
	Symptom present	46	10	1.91 (0.85, 4.31)	1.52 (0.60, 3.94)	32	24	5.13 (2.73, 9.68)	4.41 (2.17, 9.07)
Chills	Symptom absent	1,083	102	ref.	ref.	1,078	107	ref.	ref.
	Symptom present	73	14	1.99 (1.01, 3.92)	1.55 (0.71, 3.39)	50	37	5.90 (3.46, 10.0)	6.16 (3.45, 10.9)
Headache	Symptom absent	997	94	ref.	ref.	999	92	ref.	ref.
	Symptom present	159	22	1.44 (0.83, 2.50)	1.06 (0.57, 1.97)	129	52	3.63 (2.36, 5.60)	3.53 (2.24, 5.59)
Tickle in throat	Symptom absent	1,101	111	ref.	ref.	1,083	129	ref.	ref.
	Symptom present	55	5	0.93 (0.32, 2.67)	1.00 (0.31, 3.07)	45	15	2.48 (1.22, 5.01)	2.47 (1.14, 5.32)
Sore throat	Symptom absent	1,044	103	ref.	ref.	1,038	109	ref.	ref.
	Symptom present	112	13	0.86 (0.41, 1.79)	0.72 (0.32, 1.60)	90	35	2.76 (1.68, 4.52)	2.96 (1.73, 5.09)
Myalgia	Symptom absent	1,060	103	ref.	ref.	1,066	97	ref.	ref.
	Symptom present	96	13	1.11 (0.55, 2.26)	0.62 (0.27, 1.44)	62	47	6.09 (3.76, 9.85)	7.08 (4.17, 12.0)
Chest pain	Symptom absent	1,130	111	ref.	ref.	1,109	132	ref.	ref.
	Symptom present	26	5	1.16 (0.34, 4.03)	0.60 (0.15, 2.41)	19	12	4.00 (1.73, 9.27)	3.55 (1.44, 8.81)
Sinus pressure	Symptom absent	1,135	112	ref.	ref.	1,112	135	ref.	ref.

Swollen glands	Symptom present	21	4	2.10 (0.58, 1.73)	1.93 (0.40, 8.75)	16	9	3.38 (1.19, 9.69)	2.83 (0.84, 9.78)
	Symptom absent	1,137	111	ref.	ref.	1,112	136	ref.	ref.
Loss of appetite	Symptom present	19	5	1.36 (0.29, 5.85)	0.96 (0.16, 5.20)	16	8	2.12 (0.66, 6.78)	1.63 (0.40, 6.46)
	Symptom absent	1,116	111	ref.	ref.	1,105	122	ref.	ref.
Difficulty breathing	Symptom present	40	5	1.42 (0.53, 3.78)	1.11 (0.36, 3.40)	23	22	7.86 (3.94, 15.7)	9.57 (4.36, 20.8)
	Symptom absent	1,124	106	ref.	ref.	1,107	123	ref.	ref.
Wheeze	Symptom present	32	10	3.04 (1.32, 7.03)	1.79 (0.65, 4.82)	21	21	8.13 (3.94, 16.8)	7.22 (3.29, 15.8)
	Symptom absent	1,141	113	ref.	ref.	1,117	137	ref.	ref.
Shortness of breath	Symptom present	15	3	1.44 (0.31, 6.68)	1.08 (0.18, 6.47)	11	7	3.30 (1.06, 10.3)	3.41 (0.97, 12.1)
	Symptom absent	1,137	109	ref.	ref.	1,121	125	ref.	ref.
Diarrhea	Symptom present	19	7	3.61 (1.35, 9.73)	1.65 (0.45, 6.09)	7	19	28.9 (9.37, 88.5)	27.9 (8.29, 95.7)
	Symptom absent	1,115	113	ref.	ref.	1,100	128	ref.	ref.
Nausea	Symptom present	41	3	0.68 (0.20, 2.30)	0.46 (0.12, 1.76)	28	16	3.75 (1.89, 7.44)	4.97 (2.31, 10.6)
	Symptom absent	1,113	109	ref.	ref.	1,093	129	ref.	ref.
Stomach pain	Symptom present	43	7	1.42 (0.53, 3.73)	1.36 (0.47, 3.88)	35	15	2.73 (1.32, 5.63)	2.54 (1.15, 5.60)
	Symptom absent	1,106	112	ref.	ref.	1,092	126	ref.	ref.
Difficulty thinking	Symptom present	50	4	0.59 (0.18, 1.99)	0.47 (0.13, 1.71)	36	18	3.20 (1.65, 6.20)	3.69 (1.79, 7.52)
	Symptom absent	1,135	113	ref.	ref.	1,111	137	ref.	ref.
Fatigue	Symptom present	21	3	0.54 (0.07, 4.19)	0.27 (0.02, 3.09)	17	7	2.80 (0.95, 8.19)	2.43 (0.69, 8.56)
	Symptom absent	1,062	102	ref.	ref.	1,052	112	ref.	ref.
Loss of taste	Symptom present	94	14	1.49 (0.77, 2.88)	1.16 (0.55, 2.42)	76	32	3.66 (2.21, 6.03)	3.80 (2.21, 6.51)
	Symptom absent	1,122	112	ref.	ref.	1,115	119	ref.	ref.
Loss of smell	Symptom present	34	4	0.94 (0.27, 3.16)	0.69 (0.15, 3.16)	13	25	12.9 (5.94, 28.0)	16.1 (6.67, 38.9)
	Symptom absent	1,127	112	ref.	ref.	1,118	121	ref.	ref.
Pain in eyes	Symptom present	29	4	1.01 (0.30, 3.45)	0.71 (0.15, 3.50)	10	23	16.5 (7.18, 37.8)	18.1 (7.07, 46.5)
	Symptom absent	1,131	112	ref.	ref.	1,107	136	ref.	ref.
	Symptom present	25	4	1.23 (0.36, 4.26)	0.76 (0.18, 3.27)	21	8	2.11 (0.81, 5.50)	1.36 (0.45, 4.19)

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets. Counts include participants in the primary and expanded study populations; unadjusted and adjusted odds ratios are computed using data from the primary study population only.

Table S7: Association of clinical symptoms with detection of pneumococcus, stratifying by SARS-CoV-2 infection status.

Symptom	SARS-CoV-2 detection	Symptom presence	Total sample			
			Pneumococcus not detected	Pneumococcus detected	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Dry cough	Not detected	Symptom absent	1,003	80	ref.	ref.
		Symptom present	41	4	1.47 (0.50, 4.31)	1.98 (0.63, 6.18)
	Detected	Symptom absent	84	25	ref.	ref.
		Symptom present	28	7	0.83 (0.29, 2.38)	0.89 (0.21, 3.81)
Productive cough	Not detected	Symptom absent	1,001	81	ref.	ref.
		Symptom present	43	3	0.89 (0.26, 2.99)	1.05 (0.30, 3.68)
	Detected	Symptom absent	94	25	ref.	ref.
		Symptom present	18	7	0.91 (0.30, 2.82)	0.57 (0.11, 3.07)
Pressure in ears	Not detected	Symptom absent	1,031	81	ref.	ref.
		Symptom present	13	3	3.14 (0.85, 11.7)	4.87 (1.07, 23.3)
	Detected	Symptom absent	105	28	ref.	ref.
		Symptom present	7	4	1.42 (0.33, 6.25)	0.33 (0.00, 11.6)
Blocked nose	Not detected	Symptom absent	996	81	ref.	ref.
		Symptom present	48	3	0.97 (0.29, 3.28)	0.98 (0.27, 3.54)
	Detected	Symptom absent	91	27	ref.	ref.
		Symptom present	21	5	0.52 (0.14, 1.97)	0.14 (0.02, 1.21)
Runny nose	Not detected	Symptom absent	979	77	ref.	ref.
		Symptom present	65	7	1.26 (0.48, 3.34)	1.31 (0.47, 3.66)
	Detected	Symptom absent	92	27	ref.	ref.
		Symptom present	20	5	0.58 (0.15, 2.23)	0.36 (0.05, 2.30)
Sneezing	Not detected	Symptom absent	943	80	ref.	ref.
		Symptom present	101	4	0.48 (0.15, 1.60)	0.54 (0.16, 1.83)
	Detected	Symptom absent	93	25	ref.	ref.
		Symptom present	19	7	0.72 (0.19, 2.81)	1.80 (0.25, 13.2)
Watery eyes	Not detected	Symptom absent	986	83	ref.	ref.
		Symptom present	58	1	0.27 (0.04, 2.07)	0.25 (0.03, 2.02)
	Detected	Symptom absent	98	28	ref.	ref.
		Symptom present	14	4	0.46 (0.09, 2.28)	--
Hoarse voice	Not detected	Symptom absent	1,012	82	ref.	ref.
		Symptom present	32	2	0.81 (0.19, 3.59)	0.80 (0.17, 3.70)
	Detected	Symptom absent	97	27	ref.	ref.
		Symptom present	15	5	0.69 (0.18, 2.72)	0.66 (0.07, 5.94)
Fever	Not detected	Symptom absent	1,020	81	ref.	ref.
		Symptom present	24	3	1.80 (0.52, 6.36)	2.28 (0.59, 8.94)
	Detected	Symptom absent	89	21	ref.	ref.
		Symptom present	23	11	1.33 (0.50, 3.56)	1.69 (0.46, 6.11)
Sweating	Not detected	Symptom absent	1,015	81	ref.	ref.
		Symptom present	29	3	1.58 (0.46, 5.54)	2.00 (0.52, 7.73)
	Detected	Symptom absent	95	25	ref.	ref.
		Symptom present				

Chills		Symptom present	17	7	1.03 (0.33, 3.25)	1.11 (0.21, 5.89)
	Not detected	Symptom absent	998	80	ref.	ref.
Headache	Detected	Symptom present	46	4	1.49 (0.50, 4.35)	1.76 (0.56, 5.48)
		Symptom absent	85	22	ref.	ref.
	Not detected	Symptom present	27	10	1.04 (0.39, 2.78)	1.20 (0.34, 4.22)
		Symptom absent	924	75	ref.	ref.
Tickle in throat	Detected	Symptom present	120	9	1.26 (0.60, 2.61)	1.25 (0.58, 2.67)
		Symptom absent	73	19	ref.	ref.
	Not detected	Symptom present	39	13	0.86 (0.34, 2.18)	0.56 (0.16, 1.89)
		Symptom absent	1,002	81	ref.	ref.
Sore throat	Detected	Symptom present	42	3	1.30 (0.38, 4.38)	1.95 (0.53, 6.87)
		Symptom absent	99	30	ref.	ref.
	Not detected	Symptom present	13	2	0.27 (0.03, 2.27)	0.35 (0.03, 4.17)
		Symptom absent	958	80	ref.	ref.
Myalgia	Detected	Symptom present	86	4	0.49 (0.15, 1.62)	0.58 (0.17, 1.93)
		Symptom absent	86	23	ref.	ref.
	Not detected	Symptom present	26	9	0.80 (0.28, 2.29)	0.72 (0.18, 2.84)
		Symptom absent	984	82	ref.	ref.
Chest pain	Detected	Symptom present	60	2	0.50 (0.12, 2.08)	0.52 (0.11, 2.23)
		Symptom absent	76	21	ref.	ref.
	Not detected	Symptom present	36	11	0.70 (0.27, 1.85)	0.43 (0.11, 1.66)
		Symptom absent	1,026	83	ref.	ref.
Sinus pressure	Detected	Symptom present	18	1	0.81 (0.10, 6.45)	0.56 (0.06, 5.08)
		Symptom absent	104	28	ref.	ref.
	Not detected	Symptom present	8	4	0.75 (0.15, 3.88)	0.95 (0.10, 9.55)
		Symptom absent	1,029	83	ref.	ref.
Swollen glands	Detected	Symptom present	15	1	1.49 (0.18, 10.8)	3.42 (0.38, 29.7)
		Symptom absent	106	29	ref.	--
	Not detected	Symptom present	6	3	1.41 (0.24, 8.30)	--
		Symptom absent	1,029	83	ref.	ref.
Loss of appetite	Detected	Symptom present	15	1	1.14 (0.14, 8.05)	2.20 (0.22, 19.2)
		Symptom absent	108	28	ref.	--
	Not detected	Symptom present	4	4	0.92 (0.09, 9.41)	--
		Symptom absent	1,023	82	ref.	ref.
Difficulty breathing	Detected	Symptom present	21	2	1.76 (0.38, 7.79)	2.44 (0.45, 12.8)
		Symptom absent	93	29	ref.	ref.
	Not detected	Symptom present	19	3	0.52 (0.14, 1.97)	0.55 (0.12, 2.58)
		Symptom absent	1,026	81	ref.	ref.
Wheeze	Detected	Symptom present	18	3	3.18 (0.86, 11.5)	4.07 (0.96, 16.9)
		Symptom absent	98	25	ref.	ref.
	Not detected	Symptom present	14	7	1.25 (0.39, 4.00)	0.95 (0.17, 5.30)
		Symptom absent	1,033	84	--	--
	Detected	Symptom present	11	0	--	--

		Symptom absent	108	29	ref.	--
		Symptom present	4	3	1.90 (0.30, 12.2)	--
Shortness of breath	Not detected	Symptom absent	1,037	84	--	--
		Symptom present	7	0	--	--
Diarrhea	Detected	Symptom absent	100	25	ref.	ref.
		Symptom present	12	7	1.94 (0.63, 6.04)	2.39 (0.50, 11.7)
	Not detected	Symptom absent	1,016	84	--	--
		Symptom present	28	0	--	--
Nausea	Detected	Symptom absent	99	29	ref.	ref.
		Symptom present	13	3	0.71 (0.18, 2.79)	1.16 (0.12, 11.7)
	Not detected	Symptom absent	1,011	82	ref.	ref.
		Symptom present	33	2	1.17 (0.26, 4.69)	1.26 (0.27, 5.56)
Stomach pain	Detected	Symptom absent	102	27	ref.	ref.
		Symptom present	10	5	0.91 (0.23, 3.71)	1.65 (0.25, 11.1)
	Not detected	Symptom absent	1,009	83	ref.	ref.
		Symptom present	35	1	0.37 (0.05, 2.85)	0.38 (0.05, 3.34)
Difficulty thinking	Detected	Symptom absent	97	29	ref.	ref.
		Symptom present	15	3	0.49 (0.10, 2.38)	0.63 (0.09, 4.73)
	Not detected	Symptom absent	1,028	83	ref.	ref.
		Symptom present	16	1	0.94 (0.12, 7.51)	0.91 (0.08, 10.5)
Fatigue	Detected	Symptom absent	107	30	--	--
		Symptom present	5	2	--	--
	Not detected	Symptom absent	972	80	ref.	ref.
		Symptom present	72	4	0.89 (0.31, 2.52)	0.84 (0.28, 2.49)
Loss of taste	Detected	Symptom absent	90	22	ref.	ref.
		Symptom present	22	10	1.19 (0.45, 3.20)	1.20 (0.35, 4.18)
	Not detected	Symptom absent	1,031	84	--	--
		Symptom present	13	0	--	--
Loss of smell	Detected	Symptom absent	91	28	ref.	ref.
		Symptom present	21	4	0.55 (0.15, 2.12)	0.96 (0.13, 6.77)
	Not detected	Symptom absent	1,034	84	--	--
		Symptom present	10	0	--	--
Pain in eyes	Detected	Symptom absent	93	28	ref.	ref.
		Symptom present	19	4	0.52 (0.14, 1.97)	0.74 (0.10, 5.29)
	Not detected	Symptom absent	1,023	84	--	--
		Symptom present	21	0	--	--
		Symptom absent	108	28	ref.	--
		Symptom present	4	4	2.95 (0.56, 15.9)	--

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C_T values below 40 for both the *lytA* and *piaB* targets. Counts include participants in the primary and expanded study populations; unadjusted and adjusted odds ratios are computed using data from the primary study population only. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.

Table S8: Association of SARS-CoV-2 infection with pneumococcal carriage at *lytA* C_T<35 and *piaB* C_T<35 detection thresholds.

Participants	Total sample		Clinic sample		Outreach sample	
	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Total sample	3.89 (2.03, 7.46)	4.53 (2.20, 9.41)	5.54 (2.61, 11.7)	6.70 (2.80, 15.9)	0.91 (0.12, 6.97)	1.88 (0.20, 17.4)
Any symptoms in prior two weeks	4.07 (1.39, 12.1)	4.80 (1.36, 17.1)	4.42 (1.35, 15.4)	6.81 (1.39, 34.5)	--	--
No symptoms in prior two weeks	4.09 (1.66, 9.94)	4.32 (1.55, 12.1)	7.56 (2.67, 21.4)	10.4 (2.80, 39.3)	--	--

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C_T values below 35 for both the *lytA* and *piaB* targets. Data include participants enrolled in the primary study only. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.

Table S9: Association of salivary SARS-CoV-2 C_T values with pneumococcal carriage detection.

Population		Association with SARS-CoV-2 N gene c _T		Association with SARS-CoV-2 E gene c _T	
		Unadjusted β (95% CI)	Adjusted β (95% CI)	Unadjusted β (95% CI)	Adjusted β (95% CI)
Total sample	Total sample	-1.06 (-3.67, 1.55)	0.08 (-2.71, 2.85)	-1.21 (-3.71, 1.29)	-0.18 (-2.85, 2.48)
	Any symptoms in prior two weeks	-1.22 (-4.33, 1.89)	0.79 (-2.78, 4.33)	-1.27 (-4.25, 1.70)	0.53 (-2.99, 4.00)
	No symptoms in prior two weeks	-1.13 (-6.04, 3.78)	--	-1.58 (-6.28, 3.12)	--
Clinic sample	Total sample	-1.26 (-4.07, 1.56)	0.65 (-2.70, 4.02)	-1.47 (-4.24, 1.30)	0.37 (-2.89, 3.66)
	Any symptoms in prior two weeks	-1.29 (-4.79, 2.21)	1.71 (-3.60, 7.13)	-1.40 (-4.89, 2.09)	1.61 (-3.65, 6.94)
	No symptoms in prior two weeks	-1.13 (-5.96, 3.70)	--	-1.58 (-6.18, 3.01)	--
Outreach sample	Total sample	0.20 (-6.97, 7.37)	--	0.46 (-6.08, 7.00)	--
	Any symptoms in prior two weeks	-0.90 (-8.16, 6.37)	--	-0.67 (-6.94, 5.60)	--
	No symptoms in prior two weeks	--	--	--	--

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, as detected by clinical transcription-mediated amplification testing from oropharyngeal specimens; OR: odds ratio. Pneumococcal detection was defined as C_T values below 35 for both the *lytA* and *piaB* targets. Adjusted analyses include data from participants enrolled in the primary study only. We indicate dashes where models lacked sufficient sample to converge for all parameter estimates.




Figure S1: Correlation between *lytA* and *piaB* C_T values among pneumococcal carriers. Panels illustrate C_T values for all individuals found to carry pneumococci (based on C_T for both *lytA* and *piaB*; left) and for individuals with C_T values below 35 for both *lytA* and *piaB* (right).




Figure S2: Correlation of qPCR C_T value for SARS-CoV-2 and pneumococcal gene targets in saliva samples. Panels illustrate C_T values for the SARS-CoV-2 nucleocapsid (N; top panels) and structural envelope protein (E; bottom panels) genes against C_T values for the pneumococcal *lytA* (left panels) and *piaB* (right panels) genes. Data are subset to individuals found to be infected with SARS-CoV-2 and to carry pneumococci.